MARKET

AXSM

AXSM

Axsome
NASDAQ

Real-time Quotes | Nasdaq Last Sale

48.59
-1.98
-3.92%
After Hours: 50.00 +1.41 +2.90% 19:55 07/30 EDT
OPEN
50.49
PREV CLOSE
50.57
HIGH
50.49
LOW
48.34
VOLUME
488.30K
TURNOVER
--
52 WEEK HIGH
90.00
52 WEEK LOW
48.34
MARKET CAP
1.83B
P/E (TTM)
-18.1924
1D
5D
1M
3M
1Y
5Y
Were Hedge Funds Right About Dumping Axsome Therapeutics, Inc. (AXSM)?
In this article we will analyze whether Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense ...
Insider Monkey · 5d ago
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Axsome Therapeutics, Inc. (AXSM) Investigation
NEW YORK, NY / ACCESSWIRE / July 15, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Axsome Therapeutics, Inc. ('Axsome" or 'the Company') (NASDAQ:AXSM).
ACCESSWIRE · 07/15 15:00
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag
Zacks.com · 07/15 14:05
Axsome Therapeutics to Report Second Quarter 2021 Financial Results on August 9, 2021
Axsome to host conference call and webcast on Monday, August 9, 2021 at 8:00 AM Eastern Time
GlobeNewswire · 07/15 11:00
Axsome defended by analysts despite regulatory setback for narcolepsy therapy
syahrir maulana/iStock via Getty Images Axsome Therapeutics ([[AXSM]] -6.8%) is likely to record its biggest one-day loss since March after the company said that the FDA has removed the Breakthrough
Seekingalpha · 07/14 17:42
Axsome breakthrough therapy designation for narcolepsy therapy removed by FDA
syahrir maulana/iStock via Getty Images Axsome Therapeutics ([[AXSM]] -1.6%) announced that the FDA has canceled the Breakthrough Therapy Designation granted for AXS-12, a product candidate targeting cataplexy in narcolepsy. The
Seekingalpha · 07/14 13:58
BRIEF-Axsome Therapeutics - FDA Is Rescinding Co's Breakthrough Therapy Designation For Its Axs-12 Product Candidate
reuters.com · 07/13 21:00
Axsome Therapeutics National Institutes Of Health ClinicalTrials.gov Study Record Detail For Co.'s 'Open-Label Safety Study of AXS-05 in Subjects With Alzheimer's Disease Agitation,' Study Is Recruiting
https://clinicaltrials.gov/ct2/show/NCT04947553
Benzinga · 07/01 14:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AXSM. Analyze the recent business situations of Axsome through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AXSM stock price target is 140.21 with a high estimate of 225.00 and a low estimate of 62.00.
EPS
Institutional Holdings
Institutions: 258
Institutional Holdings: 27.52M
% Owned: 73.25%
Shares Outstanding: 37.57M
TypeInstitutionsShares
Increased
64
1.23M
New
33
256.13K
Decreased
51
2.17M
Sold Out
29
192.31K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
Herriot Tabuteau
Chief Financial Officer
Nick Pizzie
Chief Operating Officer
Mark Jacobson
Executive Vice President
Kevin Laliberte
Senior Vice President
Lori Englebert
Senior Vice President
Amanda Jones
Senior Vice President
Cedric O'Gorman
Lead Director/Independent Director
Roger Jeffs
Independent Director
Mark Coleman
Independent Director
Mark Saad
No Data
  • All
  • Financials
  • Insiders
More
About AXSM
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).

Webull offers kinds of Axsome Therapeutics Inc stock information, including NASDAQ:AXSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXSM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXSM stock methods without spending real money on the virtual paper trading platform.